Monopar Therapeutics Inc. (MNPR)
Monopar Therapeutics Inc. (MNPR) Stock Price, Analysis & Data
| Bid | 108.7 |
| Market Cap | 799.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -17.84M |
| Beta | 1.51 |
| EPS (ttm) | -2.26 |
| PE Ratio (ttm) | n/a |
| Forward PE | -60.13 |
| P/B (ttm) | 6.11 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 12, 2026 |
| Ask | 109.8 |
| Volume | 143,383 |
| Avg. Volume (20D) | 214,914 |
| Open | 116.65 |
| Previous Close | 116.49 |
| Day's Range | 113.79 - 119.95 |
| 52-Week Range | 29.18 - 124.82 |
| Analyst | Strong Buy |
| Price Target | 128 (7.52%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About MNPR
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and M...
Financial Performance
In 2025, Monopar Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -13.72M, a decrease of -11.99%.
Financial StatementsAnalyst Forecast
According to 13 analyst ratings, the average rating for MNPR stock is "Strong Buy". The 12-month stock price forecast is 128, which is upside of 7.52% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
6 months ago · Simply Wall St.
Institutional investors in Monopar Therapeutics Inc. (NASDAQ:MNPR) see US$66m decrease in market cap last week, although long-term gains have benefitted them.Key Insights Institutions' substantial holdings in Monopar Therapeutics implies that they have significant influence...
